{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T03:05:01Z","timestamp":1777172701592,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.beha.2008.08.004","type":"journal-article","created":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T11:13:33Z","timestamp":1227870813000},"page":"647-658","source":"Crossref","is-referenced-by-count":32,"title":["Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?"],"prefix":"10.1016","volume":"21","author":[{"given":"Dan","family":"Douer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2008.08.004_bib1","series-title":"Cancer medicine","first-page":"1027","article-title":"Asparaginase","author":"Kurtzberg","year":"1997"},{"key":"10.1016\/j.beha.2008.08.004_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib3","first-page":"802a","article-title":"Intensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05\/93","volume":"98","author":"Goekbuget","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib4","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib5","doi-asserted-by":"crossref","first-page":"521a","DOI":"10.1182\/blood.V106.11.1833.1833","article-title":"Daunorubicin dose intensification during treatment of adult acute lymphoblastic leukemia (ALL): vinal results from Cancer and Leukemia Group B Study 19802","volume":"106","author":"Stock","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib6","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib7","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2008.08.004_bib8","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/0006-2952(69)90375-X","article-title":"l-asparaginase resistance in human leukemia\u2013asparagine synthetase","volume":"18","author":"Haskell","year":"1969","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.beha.2008.08.004_bib9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.pa.10.040170.002225","article-title":"L-asparaginase and L-asparagine metabolism","volume":"10","author":"Cooney","year":"1970","journal-title":"Annual Review of Pharmacology"},{"key":"10.1016\/j.beha.2008.08.004_bib10","first-page":"727","article-title":"The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF\/CEM\/0) and (CCRF\/CEM\/ara-C\/7A) is due to increased cellular apoptosis","volume":"18","author":"Nandy","year":"1998","journal-title":"Anticancer Research"},{"key":"10.1016\/j.beha.2008.08.004_bib11","first-page":"3893","article-title":"Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from childrens cancer study group","volume":"39","author":"Ertel","year":"1979","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2008.08.004_bib12","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia","volume":"1","author":"Nesbit","year":"1979","journal-title":"The American Journal of Pediatric Hematology\/Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/1097-0142(19820401)49:7<1378::AID-CNCR2820490713>3.0.CO;2-Z","article-title":"Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma","volume":"49","author":"Evans","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2008.08.004_bib14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1182\/blood.V96.5.1709","article-title":"Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study","volume":"96","author":"Abshire","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib15","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and leukemia group B study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib16","doi-asserted-by":"crossref","first-page":"181a","DOI":"10.1182\/blood.V110.11.588.588","article-title":"Failure of asparagine (ASN) depletion, not inadequate asparaginase (ASNase) activity, predicts relapse in standard risk (SR) childhood Acute Lymphoblastic Leukemia (ALL): a Childrens Oncology Group (COG) report","volume":"110","author":"Avramis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib17","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.leu.2401007","article-title":"Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia","volume":"12","author":"Larson","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2008.08.004_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"Woo","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: children's cancer group study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib20","first-page":"5601","article-title":"Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia","volume":"43","author":"Sallan","year":"1983","journal-title":"Cancer Research"},{"key":"10.1016\/j.beha.2008.08.004_bib21","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib22","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beha.2008.08.004_bib24","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group","volume":"95","author":"Schrappe","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib25","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib26","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib27","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","article-title":"Comparison of Escherichia coli-asparaginase with Erwinia-Asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial","volume":"99","author":"Duval","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib28","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib29","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib30","first-page":"366","article-title":"Treatment of adults with newly diagnosed acute lymphoblastic leukemia with multiple doses of intravenous pegylated asparaginase in an intensified pediatric regimen","volume":"93","author":"Srivastava","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2008.08.004_bib31","doi-asserted-by":"crossref","first-page":"181a","DOI":"10.1182\/blood.V110.11.587.587","article-title":"A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia","volume":"110","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib34","series-title":"Nelson textbook of pediatrics","first-page":"1694","article-title":"The leukemias","author":"Tubergen","year":"2003"},{"key":"10.1016\/j.beha.2008.08.004_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood.V73.1.57.57","article-title":"Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy","volume":"73","author":"Hussein","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.leu.2402006","article-title":"Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate\/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study","volume":"15","author":"Petersdorf","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2008.08.004_bib37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1046\/j.1365-2141.1997.3613175.x","article-title":"Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical research council randomized trial UKALL XA. Medical research council working party on leukaemia in adults","volume":"99","author":"Durrant","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.beha.2008.08.004_bib38","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2008.08.004_bib39","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2002.07.116","article-title":"Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia","volume":"20","author":"Linker","year":"2002","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib40","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.beha.2008.08.004_bib41","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692608000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692608000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T03:56:15Z","timestamp":1589255775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692608000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1521692608000704"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2008.08.004","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}